Lacosamide Tablet
Product Images NDC 16714-548

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Lacosamide (NDC 16714-548). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Northstar Rxllc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

100-mg (100 mg Label)

Label for Lacosamide Tablets, USP 100 mg by NorthStar Rx LLC. The label shows the NDC number 16714-549-01 and indicates 60 tablets per bottle. It includes storage instructions and manufacturer information for Indoco Remedies Ltd., India. The label has a white and blue design with a purple 100 mg strength highlight.*

FDA Label Image

150-mg (150 mg Label)

Label for Lacosamide Tablets USP, 150 mg, oral tablets, containing 60 tablets per bottle. The label shows manufacturer information as Indoco Remedies Ltd. and labeler NorthStar Rx LLC, Memphis, TN. It includes storage instructions, a barcode, and a pharmacy warning to provide the Medication Guide to each patient.*

FDA Label Image

200-mg (200 mg Label)

Bottle label for Lacosamide Tablets USP 200 mg, oral tablets by NorthStar Rx LLC. The label indicates 60 tablets per bottle and provides storage instructions, manufacturer details (Indoco Remedies Ltd, India), and a medication guide notice for pharmacists. Barcode and NDC 16714-552-01 are also shown.*

FDA Label Image

50-mg (50 mg Label)

Lacosamide Tablets USP 50 mg oral tablets label from NorthStar RxLLC. The label indicates a 60-tablet package, includes storage instructions at 20 to 25°C, and advises consulting the package insert for dosage information. Manufactured by Indoco Remedies Ltd., India, and distributed by NorthStar Rx LLC, Memphis, TN.*

FDA Label Image

Fig1 (Figure1)

Bar chart comparing median percentage seizure reduction from baseline across three studies (Study 2, Study 3, Study 4) for placebo and Lacosamide tablets at varying dosages (200 mg, 400 mg, 600 mg). Each study shows higher seizure reduction percentages for Lacosamide doses compared to placebo, with sample sizes noted below each group. Statistically significant differences versus placebo are indicated.*

FDA Label Image

Fig2 (Figure2)

A responder rate chart showing the percentage of patients on the x-axis and responder rate (equal to or greater improvement) on the y-axis. The chart compares placebo with Lacosamide tablets at doses of 200 mg/day, 400 mg/day, and 600 mg/day, each represented by different line styles. The graph illustrates the response across patient percentages for each treatment group.*

FDA Label Image

Str (Structure)

Chemical structure of lacosamide, showing its molecular framework including a phenyl group, an amide bond, and other functional groups characteristic of this compound.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.